OBJECTIVE: Ex vivo lung perfusion has been successful in the assessment of marginal donor lungs, including donation after cardiac death (DCD) donor lungs. Ex vivo lung perfusion also represents a unique platform for targeted drug delivery. We sought to determine whether ischemia-reperfusion injury would be decreased after transplantation of DCD donor lungs subjected to prolonged cold preservation and treated with an adenosine A2A receptor agonist during ex vivo lung perfusion. METHODS: Porcine DCD donor lungs were preserved at 4°C for 12 hours and underwent ex vivo lung perfusion for 4 hours. Left lungs were then transplanted and reperfused for 4 hours. Three groups (n = 4/group) were randomized according to treatment with the adenosine A2A receptor agonist ATL-1223 or the dimethyl sulfoxide vehicle: Infusion of dimethyl sulfoxide during ex vivo lung perfusion and reperfusion (DMSO), infusion of ATL-1223 during ex vivo lung perfusion and dimethyl sulfoxide during reperfusion (ATL-E), and infusion of ATL-1223 during ex vivo lung perfusion and reperfusion (ATL-E/R). Final Pao2/Fio2 ratios (arterial oxygen partial pressure/fraction of inspired oxygen) were determined from samples obtained from the left superior and inferior pulmonary veins. RESULTS: Final Pao2/Fio2 ratios in the ATL-E/R group (430.1 ± 26.4 mm Hg) were similar to final Pao2/Fio2 ratios in the ATL-E group (413.6 ± 18.8 mm Hg), but both treated groups had significantly higher final Pao2/Fio2 ratios compared with the dimethyl sulfoxide group (84.8 ± 17.7 mm Hg). Low oxygenation gradients during ex vivo lung perfusion did not preclude superior oxygenation capacity during reperfusion. CONCLUSIONS: After prolonged cold preservation, treatment of DCD donor lungs with an adenosine A2A receptor agonist during ex vivo lung perfusion enabled Pao2/Fio2 ratios greater than 400 mm Hg after transplantation in a preclinical porcine model. Pulmonary function during ex vivo lung perfusion was not predictive of outcomes after transplantation.
OBJECTIVE: Ex vivo lung perfusion has been successful in the assessment of marginal donor lungs, including donation after cardiac death (DCD) donor lungs. Ex vivo lung perfusion also represents a unique platform for targeted drug delivery. We sought to determine whether ischemia-reperfusion injury would be decreased after transplantation of DCDdonor lungs subjected to prolonged cold preservation and treated with an adenosine A2A receptor agonist during ex vivo lung perfusion. METHODS: Porcine DCDdonor lungs were preserved at 4°C for 12 hours and underwent ex vivo lung perfusion for 4 hours. Left lungs were then transplanted and reperfused for 4 hours. Three groups (n = 4/group) were randomized according to treatment with the adenosine A2A receptor agonist ATL-1223 or the dimethyl sulfoxide vehicle: Infusion of dimethyl sulfoxide during ex vivo lung perfusion and reperfusion (DMSO), infusion of ATL-1223 during ex vivo lung perfusion and dimethyl sulfoxide during reperfusion (ATL-E), and infusion of ATL-1223 during ex vivo lung perfusion and reperfusion (ATL-E/R). Final Pao2/Fio2 ratios (arterial oxygen partial pressure/fraction of inspired oxygen) were determined from samples obtained from the left superior and inferior pulmonary veins. RESULTS: Final Pao2/Fio2 ratios in the ATL-E/R group (430.1 ± 26.4 mm Hg) were similar to final Pao2/Fio2 ratios in the ATL-E group (413.6 ± 18.8 mm Hg), but both treated groups had significantly higher final Pao2/Fio2 ratios compared with the dimethyl sulfoxide group (84.8 ± 17.7 mm Hg). Low oxygenation gradients during ex vivo lung perfusion did not preclude superior oxygenation capacity during reperfusion. CONCLUSIONS: After prolonged cold preservation, treatment of DCDdonor lungs with an adenosine A2A receptor agonist during ex vivo lung perfusion enabled Pao2/Fio2 ratios greater than 400 mm Hg after transplantation in a preclinical porcine model. Pulmonary function during ex vivo lung perfusion was not predictive of outcomes after transplantation.
Authors: Andrew F Pierre; Yasuo Sekine; Michael A Hutcheon; Thomas K Waddell; Shaf H Keshavjee Journal: J Thorac Cardiovasc Surg Date: 2002-03 Impact factor: 5.209
Authors: Jason D Christie; Dirk Van Raemdonck; Marc de Perrot; Mark Barr; Shaf Keshavjee; Selim Arcasoy; Jonathan Orens Journal: J Heart Lung Transplant Date: 2005-10 Impact factor: 10.247
Authors: Jason D Christie; Martin Carby; Remzi Bag; Paul Corris; Marshall Hertz; David Weill Journal: J Heart Lung Transplant Date: 2005-06-04 Impact factor: 10.247
Authors: Jason D Christie; Jeffrey S Sager; Stephen E Kimmel; Vivek N Ahya; Christina Gaughan; Nancy P Blumenthal; Robert M Kotloff Journal: Chest Date: 2005-01 Impact factor: 9.410
Authors: T Brett Reece; Peter I Ellman; Thomas S Maxey; Ivan K Crosby; Patrick S Warren; Tae W Chong; Robin D LeGallo; Joel Linden; John A Kern; Curtis G Tribble; Irving L Kron Journal: J Thorac Cardiovasc Surg Date: 2005-05 Impact factor: 5.209
Authors: Steven M Fiser; Curtis G Tribble; Stewart M Long; Aditya K Kaza; John A Kern; David R Jones; Mark K Robbins; Irving L Kron Journal: Ann Thorac Surg Date: 2002-04 Impact factor: 4.330
Authors: Phil Botha; Dipesh Trivedi; Christopher J Weir; Cait P Searl; Paul A Corris; John H Dark; Stephan V B Schueler Journal: J Thorac Cardiovasc Surg Date: 2006-05 Impact factor: 5.209
Authors: Minqing Zhao; Lucas G Fernandez; Allan Doctor; Ashish K Sharma; Alexander Zarbock; Curtis G Tribble; Irving L Kron; Victor E Laubach Journal: Am J Physiol Lung Cell Mol Physiol Date: 2006-07-21 Impact factor: 5.464
Authors: Bryan A Whitson; Matthew E Prekker; Cynthia S Herrington; Timothy P M Whelan; David M Radosevich; Marshall I Hertz; Peter S Dahlberg Journal: J Heart Lung Transplant Date: 2007-10 Impact factor: 10.247
Authors: Leo M Gazoni; Victor E Laubach; Daniel P Mulloy; A Bellizzi; Eric B Unger; Joel Linden; Peter I Ellman; Turner C Lisle; Irving L Kron Journal: J Thorac Cardiovasc Surg Date: 2007-11-26 Impact factor: 5.209
Authors: J Hunter Mehaffey; Eric J Charles; Ashish K Sharma; Dustin T Money; Yunge Zhao; Mark H Stoler; Christine L Lau; Curtis G Tribble; Victor E Laubach; Mark E Roeser; Irving L Kron Journal: J Thorac Cardiovasc Surg Date: 2016-09-22 Impact factor: 5.209
Authors: Eric J Charles; J Hunter Mehaffey; Ashish K Sharma; Yunge Zhao; Mark H Stoler; James M Isbell; Christine L Lau; Curtis G Tribble; Victor E Laubach; Irving L Kron Journal: J Thorac Cardiovasc Surg Date: 2017-04-12 Impact factor: 5.209
Authors: James H Mehaffey; Dustin Money; Eric J Charles; Sarah Schubert; Angela Fernandez Piñeros; Di Wu; Sai Vineela Bontha; Robert Hawkins; Nicholas R Teman; Victor E Laubach; Valeria R Mas; Curtis G Tribble; Daniel G Maluf; Ashish K Sharma; Zequan Yang; Irving L Kron; Mark E Roeser Journal: Ann Surg Date: 2019-06 Impact factor: 12.969
Authors: J Hunter Mehaffey; Eric J Charles; Ashish K Sharma; Morgan Salmon; Dustin Money; Sarah Schubert; Mark H Stoler; Curtis G Tribble; Victor E Laubach; Mark E Roeser; Irving L Kron Journal: Ann Thorac Surg Date: 2017-04-21 Impact factor: 4.330
Authors: Eric J Charles; Mary E Huerter; Cynthia E Wagner; Ashish K Sharma; Yunge Zhao; Mark H Stoler; J Hunter Mehaffey; James M Isbell; Christine L Lau; Curtis G Tribble; Victor E Laubach; Irving L Kron Journal: Ann Thorac Surg Date: 2016-09-07 Impact factor: 4.330
Authors: J Hunter Mehaffey; Eric J Charles; Adishesh K Narahari; Sarah Schubert; Victor E Laubach; Nicholas R Teman; Kevin R Lynch; Irving L Kron; Ashish K Sharma Journal: J Thorac Cardiovasc Surg Date: 2018-03-11 Impact factor: 5.209